National Institute on Drug Abuse; Notice of Meeting, 1266-1267 [2018-00218]
Download as PDF
<![CDATA[
1266
Federal Register / Vol. 83, No. 7 / Wednesday, January 10, 2018 / Notices
Agenda: Discussion of program and issues.
Place: Nat. Inst. of Environmental Health
Sciences, Building 101, Rodbell Auditorium,
111 T. W. Alexander Drive, Research
Triangle Park, NC 27709.
Contact Person: Gwen W Collman, Ph.D.,
Interim Director, Division of Extramural
Research & Training National Institutes of
Health, Nat. Inst. of Environmental Health
Sciences, 615 Davis Dr., KEY615/3112,
Research Triangle Park, NC 27709 (919) 541–
4980, collman@niehs.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.niehs.nih.gov/dert/c-agenda.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: January 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–00220 Filed 1–9–18; 8:45 am]
BILLING CODE 4140–01–P
Dated: January 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2018–00217 Filed 1–9–18; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
daltland on DSKBBV9HB2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
18:23 Jan 09, 2018
Jkt 244001
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ‘‘Induction of mucosal
immune responses for parenterally delivered
vaccines’’.
Date: February 5, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G62A, National Institute of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5081,
ecohen@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; (PHS 2018–1) Small
Business Innovation Research (SBIR)
Program Contract Solicitation (Topic 53)
(N01).
Date: February 6, 2018.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Vasundhara Varthakavi,
DVM, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, Room 3E70, National
Institutes of Health, NIAID, 5601 Fishers
Lane, MSC 9823, Bethesda, MD 20892–9823,
(240) 669–5020, varthakaviv@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: February 6, 2018.
Closed: 9:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Open: 10:30 a.m. to 4:30 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative, and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, NSC, Room 5274, MSC 9591,
Rockville, MD 20892, 301–443–6487,
sweiss@nida.nih.gov.
Any member of the public interested
in presenting oral comments to the
committee may notify the Contact
Person listed on this notice at least 10
days in advance of the meeting.
Interested individuals and
representatives of organizations may
submit a letter of intent, a brief
description of the organization
represented, and a short description of
the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee,
presentations may be limited to five
minutes. Both printed and electronic
copies are requested for the record. In
addition, any interested person may file
written comments with the committee
by forwarding their statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
E:\FR\FM\10JAN1.SGM
10JAN1
Federal Register / Vol. 83, No. 7 / Wednesday, January 10, 2018 / Notices
NACDAHome.html, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–00218 Filed 1–9–18; 8:45 am]
BILLING CODE 4140–01–P
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–00219 Filed 1–9–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HOMELAND
SECURITY
National Institute on Drug Abuse;
Notice of Closed Meetings
U.S. Immigration and Customs
Enforcement
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
daltland on DSKBBV9HB2PROD with NOTICES
National Institutes of Health
[OMB Control Number 1653–0038]
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, NIH
Pathway to Independence Award (K99/R00).
Date: February 14, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel,
Pharmacogenomics of Anti-retroviral
Therapy in People Who Inject Drugs (R01).
Date: February 15, 2018.
Time: 11:00 a.m. to 1:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
VerDate Sep<11>2014
18:23 Jan 09, 2018
Jkt 244001
Agency Information Collection
Activities: Comment Request;
Extension, With Changes, of an
Information Collection
1267
should address one or more of the
following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
AGENCY:
Overview of This Information
Collection
The Department of Homeland
Security (DHS), U.S. Immigration and
Customs Enforcement (USICE) is
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and clearance in accordance
with the Paperwork Reduction Act of
1995. The information collection notice
was previously published in the Federal
Register on September 18, 2017, Vol. 82
FR 43565, allowing for a 60-day public
comment period. USICE did not receive
any comment relating to the 60-day
notice. The purpose of this notice is to
allow an additional 30 days for public
comments.
The burden estimates have been
revised since the 60-day notice to better
reflect the number of potential
respondents to the collection. Written
comments and/or suggestions regarding
the items contained in this notice,
especially regarding the estimated
public burden and associated response
time, must be directed to the OMB Desk
Officer for U.S. Immigration and
Customs Enforcement, Department of
Homeland Security and sent via
electronic mail to dhsdeskofficer@
omb.eop.gov. All submissions received
must include the agency name and the
OMB Control Number 1653–0038.
Written comments and suggestions
from the public and affected agencies
(1) Type of Information Collection:
Extension, With Changes, of a Currently
Approved Collection.
(2) Title of the Form/Collection:
Student and Exchange Visitor
Information System (SEVIS).
(3) Agency form number, if any, and
the applicable component of the
Department of Homeland Security
sponsoring the collection: Forms I–17
and I–20; U.S. Immigration and Customs
Enforcement.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary Non-profit institutions
and individuals or households. SEVIS is
an internet-based data-entry, collection
and reporting system. It collects
information on SEVP-certified schools
via the Form I–17, ‘‘Petition for
Approval of School for Attendance by
Nonimmigrant Student,’’ and collects
information on the F and M
nonimmigrant students that the SEVPcertified schools admit into their
programs of study via the Forms I–20s:
‘‘Certificate of Eligibility for
Nonimmigrant (F–1) Student Status—
For Academic and Language Students’’
and ‘‘Certificate of Eligibility for
Nonimmigrant (M–1) Student Status—
For Vocational Students’’.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond:
U.S. Immigration and Customs
Enforcement, Department of Homeland
Security.
ACTION: 30-day notice.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
E:\FR\FM\10JAN1.SGM
10JAN1
]]>Agencies
[Federal Register Volume 83, Number 7 (Wednesday, January 10, 2018)]
[Notices]
[Pages 1266-1267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00218]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: February 6, 2018.
Closed: 9:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Open: 10:30 a.m. to 4:30 p.m.
Agenda: This portion of the meeting will be open to the public
for announcements and reports of administrative, legislative, and
program developments in the drug abuse field.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC
9591, Rockville, MD 20892, 301-443-6487, [email protected].
Any member of the public interested in presenting oral comments to
the committee may notify the Contact Person listed on this notice at
least 10 days in advance of the meeting. Interested individuals and
representatives of organizations may submit a letter of intent, a brief
description of the organization represented, and a short description of
the oral presentation. Only one representative of an organization may
be allowed to present oral comments and if accepted by the committee,
presentations may be limited to five minutes. Both printed and
electronic copies are requested for the record. In addition, any
interested person may file written comments with the committee by
forwarding their statement to the Contact Person listed on this notice.
The statement should include the name, address, telephone number and
when applicable, the business or professional affiliation of the
interested person.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/
[[Page 1267]]
NACDAHome.html, where an agenda and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: January 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-00218 Filed 1-9-18; 8:45 am]
BILLING CODE 4140-01-P
